10 Practical guidelines for better health economic evaluations

For many non-health-economists, understanding what makes a health economic evaluation robust and decision-relevant isn't always straightforward. 

Whether an evaluation withstands scrutiny usually comes down to a handful of choices:

  • who was studied
  • what the treatment was compared against
  • from whose perspective
  • over what time horizon
  • how uncertainty was handled

To support pharma professionals who work with health economic data, whether in Medical Affairs, Market Access or Marketing, Prof. Dr Lieven Annemans has listed 10 guidelines that reflect international best practice.

1. Clearly define the medical problem and patient population


Economic models must start with a well-defined patient population. Vague definitions like “patients at risk of stroke” don’t provide enough context for meaningful conclusions. A good example: “Spinal cord stimulation in patients with failed back surgery, average age 52, with predominantly back pain and an average pain duration of 4 years.”
 

2. Choose the most relevant comparator


Cost-effectiveness is always relative. The new treatment should be compared to the most likely alternative in clinical practice, not a placebo or outdated option. A thorough description of both treatment strategies is important, including known side effects and usage patterns.
 

3. Be clear about the evaluation perspective


Is the analysis conducted from a payer, healthcare system, or societal perspective? This matters. For instance, the societal perspective might include productivity losses, especially relevant in diseases like depression, while payer perspectives often do not.
 

4. Make the model transparent and validate its outcomes


The assumptions behind the model should be clearly explained. Where possible, model outputs should be validated against real-world data. For example: comparing predicted stroke rates under current care with those observed in practice.
 

5. Use realistic and well-sourced cost estimates


Costs should be broken down into all relevant components (e.g. acute care, follow-up, re-admissions) and linked to the defined patient population. All sources must be disclosed. Over-simplified assumptions can lead to misleading results.
 

6. Use reliable clinical inputs and appropriate outcomes


Data inputs should come from high-quality sources and reflect the population being studied. When it comes to outcomes, the QALY remains the standard across many countries. Using the most relevant data for the base case is key.
 

7. Choose a time horizon that reflects the full impact


The time horizon should be long enough to capture all significant costs and effects. Results should be tested for different horizons to show how conclusions might change over time.
 

8. Thoroughly analyse uncertainty


Every model involves uncertainty. High-quality evaluations include sensitivity analyses, both one-way (e.g. Tornado diagrams) and probabilistic (PSA), to show how results vary with changes in key inputs and assumptions.
 

9. Apply appropriate discounting


If the time horizon extends beyond one year, future costs and benefits should be discounted. Including alternative discount rates in sensitivity analysis is good practice.
 

10. Be specific and well-reasoned in your conclusions


A strong conclusion is based on the PICOS framework: Patient, Intervention, Comparator, Outcome, and Study Design. Rather than saying “the treatment is cost-effective,” clarify for whom, compared to what, and over what time frame.


These 10 guidelines are increasingly important as health economic evaluations influence funding, pricing, and access decisions in a growing number of countries. By applying or recognising these principles, you can better evaluate evidence and contribute to stronger, more credible value communications.
 

Download the Health Economic Evaluation Review Tool

Health Economic Evaluation Review Tool
I accept that relevant personal details are stored in a database for that purpose, as per our Privacy Policy, of which I accept the terms. *

Continue your learning from Lieven

If you’d like to learn more from Lieven, CELforPharma also offers a 2-day, hands-on course where you'll learn how to:

  • Understand the fundamentals of cost-effectiveness, cost-utility, and budget-impact analysis
  • Interpret and talk about health-economic data confidently in cross-functional discussions
  • Communicate value more effectively with payers, KOLs, and other stakeholders
  • Integrate health economic thinking into product-strategy discussions across development, medical, and commercial functions

Don’t miss the latest insights from our expert faculty

Subscribe to our newsletter to:

  • Stay on top of the latest expert insights
  • Receive invitations to upcoming educational webinars
  • Get updates on our courses and training programmes